{"id":"https://openalex.org/W4385669757","doi":"https://doi.org/10.1192/j.eurpsy.2023.345","title":"Long-term efficacy and safety of paliperidone 6-month formulation: An open-label extension of a double-blind study in adult patients with schizophrenia","display_name":"Long-term efficacy and safety of paliperidone 6-month formulation: An open-label extension of a double-blind study in adult patients with schizophrenia","publication_year":2023,"publication_date":"2023-03-01","ids":{"openalex":"https://openalex.org/W4385669757","doi":"https://doi.org/10.1192/j.eurpsy.2023.345"},"language":"en","primary_location":{"id":"doi:10.1192/j.eurpsy.2023.345","doi":"https://doi.org/10.1192/j.eurpsy.2023.345","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1192/j.eurpsy.2023.345","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/44F9A169772F20EDAEE9079BEC096BB3/S0924933823003450a.pdf/div-class-title-long-term-efficacy-and-safety-of-paliperidone-6-month-formulation-an-open-label-extension-of-a-double-blind-study-in-adult-patients-with-schizophrenia-div.pdf","source":{"id":"https://openalex.org/S87202501","display_name":"European Psychiatry","issn_l":"0924-9338","issn":["0924-9338","1778-3585"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Psychiatry","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/44F9A169772F20EDAEE9079BEC096BB3/S0924933823003450a.pdf/div-class-title-long-term-efficacy-and-safety-of-paliperidone-6-month-formulation-an-open-label-extension-of-a-double-blind-study-in-adult-patients-with-schizophrenia-div.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064130565","display_name":"Dean M. Najarian","orcid":"https://orcid.org/0000-0002-2556-2144","observed_orcids":["https://orcid.org/0000-0002-2556-2144"]},"institutions":[{"id":"https://openalex.org/I4391767992","display_name":"Janssen Scientific Affairs (United States)","ror":"https://ror.org/04w4xsz15","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4391767992"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Najarian","raw_affiliation_strings":["Janssen Scientific Affairs, LLC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Scientific Affairs, LLC","institution_ids":["https://openalex.org/I4391767992"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071518287","display_name":"Ibrahim Turkoz","orcid":"https://orcid.org/0000-0003-1891-2297","observed_orcids":["https://orcid.org/0000-0003-1891-2297"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I. Turkoz","raw_affiliation_strings":["Janssen Research & Development, LLC, Titusville, NJ, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, LLC, Titusville, NJ, United States","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032931781","display_name":"Silvana Galderisi","orcid":"https://orcid.org/0000-0002-1592-7656","observed_orcids":["https://orcid.org/0000-0002-1592-7656"]},"institutions":[{"id":"https://openalex.org/I197809005","display_name":"University of Campania \"Luigi Vanvitelli\"","ror":"https://ror.org/02kqnpp86","country_code":"IT","type":"education","lineage":["https://openalex.org/I197809005"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"S. Galderisi","raw_affiliation_strings":["University of Campania \u201cLuigi Vanvitelli\u201d, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Campania \u201cLuigi Vanvitelli\u201d, Naples, Italy","institution_ids":["https://openalex.org/I197809005"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092524685","display_name":"Hector F Lamaison","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I874386039","display_name":"Universidad Nacional de La Plata","ror":"https://ror.org/01tjs6929","country_code":"AR","type":"education","lineage":["https://openalex.org/I874386039"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"H. F. Lamaison","raw_affiliation_strings":["Department of Psychiatry, National University of La Plata (UNLP), Buenos Aires, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Psychiatry, National University of La Plata (UNLP), Buenos Aires, Argentina","institution_ids":["https://openalex.org/I874386039"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5092524686","display_name":"Piotr Zalitacz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Zalitacz","raw_affiliation_strings":["Head of Psychiatric Unit, Gorlice Specialist Hospital, Gorlice, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Head of Psychiatric Unit, Gorlice Specialist Hospital, Gorlice, Poland","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"S. Aravind","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Aravind","raw_affiliation_strings":["Janssen Research & Development, LLC, Titusville, NJ, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, LLC, Titusville, NJ, United States","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021030323","display_name":"Ute Richarz","orcid":"https://orcid.org/0000-0001-5928-7905","observed_orcids":["https://orcid.org/0000-0001-5928-7905"]},"institutions":[{"id":"https://openalex.org/I4391767734","display_name":"Cilag (Switzerland)","ror":"https://ror.org/02fe4h741","country_code":"CH","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210113301","https://openalex.org/I4391767734"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"U. Richarz","raw_affiliation_strings":["Janssen Research & Development-Cilag, Gubelstrasse, Zug, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development-Cilag, Gubelstrasse, Zug, Switzerland","institution_ids":["https://openalex.org/I4391767734"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5021030323"],"corresponding_institution_ids":["https://openalex.org/I4391767734"],"apc_list":{"value":2785,"currency":"USD","value_usd":2785},"apc_paid":{"value":2785,"currency":"USD","value_usd":2785},"fwci":null,"has_fulltext":true,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"66","issue":"S1","first_page":"S136","last_page":"S136"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12980","display_name":"Family Caregiving in Mental Illness","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3203","display_name":"Clinical Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12308","display_name":"Mental Health and Psychiatry","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1211","display_name":"Philosophy"},"field":{"id":"https://openalex.org/fields/12","display_name":"Arts and Humanities"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.8130000233650208},{"id":"https://openalex.org/keywords/long-term-efficacy","display_name":"long-term efficacy","score":0.7699999809265137},{"id":"https://openalex.org/keywords/relapse-prevention","display_name":"relapse prevention","score":0.9240000247955322},{"id":"https://openalex.org/keywords/long-acting-injectable-antipsychotics","display_name":"long-acting injectable antipsychotics","score":0.8159999847412109},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.7889999747276306},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.9010000228881836},{"id":"https://openalex.org/keywords/prolactin-elevation","display_name":"prolactin elevation","score":0.7649999856948853},{"id":"https://openalex.org/keywords/positive-and-negative-syndrome-scale","display_name":"PANSS","score":0.8600000143051147},{"id":"https://openalex.org/keywords/personal-and-social-performance","display_name":"Personal and Social Performance","score":0.7960000038146973},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.30300000309944153},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.5590000152587891}],"concepts":[{"id":"https://openalex.org/C2777126507","wikidata":"https://www.wikidata.org/wiki/Q423292","display_name":"Paliperidone","level":4,"score":0.7596261501312256},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6625649333000183},{"id":"https://openalex.org/C2780135775","wikidata":"https://www.wikidata.org/wiki/Q7233251","display_name":"Positive and Negative Syndrome Scale","level":3,"score":0.6585572957992554},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6361294984817505},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.5905285477638245},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5796536803245544},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5453391671180725},{"id":"https://openalex.org/C2908997079","wikidata":"https://www.wikidata.org/wiki/Q27157250","display_name":"Paliperidone Palmitate","level":4,"score":0.5338730812072754},{"id":"https://openalex.org/C2776000289","wikidata":"https://www.wikidata.org/wiki/Q5133761","display_name":"Clinical Global Impression","level":4,"score":0.5066179037094116},{"id":"https://openalex.org/C2777393122","wikidata":"https://www.wikidata.org/wiki/Q416417","display_name":"Akathisia","level":4,"score":0.44951772689819336},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.39179152250289917},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.2757219970226288},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.21893411874771118},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.2044726312160492},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.1293812096118927},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1192/j.eurpsy.2023.345","doi":"https://doi.org/10.1192/j.eurpsy.2023.345","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1192/j.eurpsy.2023.345","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/44F9A169772F20EDAEE9079BEC096BB3/S0924933823003450a.pdf/div-class-title-long-term-efficacy-and-safety-of-paliperidone-6-month-formulation-an-open-label-extension-of-a-double-blind-study-in-adult-patients-with-schizophrenia-div.pdf","source":{"id":"https://openalex.org/S87202501","display_name":"European Psychiatry","issn_l":"0924-9338","issn":["0924-9338","1778-3585"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Psychiatry","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10595946","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10595946","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10595946/pdf/S0924933823003450a.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Eur Psychiatry","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:db40b827d4494e53a2a4ae779241a986","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/db40b827d4494e53a2a4ae779241a986","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"European Psychiatry, Vol 66, Pp S136-S136 (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1192/j.eurpsy.2023.345","doi":"https://doi.org/10.1192/j.eurpsy.2023.345","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1192/j.eurpsy.2023.345","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/44F9A169772F20EDAEE9079BEC096BB3/S0924933823003450a.pdf/div-class-title-long-term-efficacy-and-safety-of-paliperidone-6-month-formulation-an-open-label-extension-of-a-double-blind-study-in-adult-patients-with-schizophrenia-div.pdf","source":{"id":"https://openalex.org/S87202501","display_name":"European Psychiatry","issn_l":"0924-9338","issn":["0924-9338","1778-3585"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Psychiatry","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4385669757.pdf","grobid_xml":"https://content.openalex.org/works/W4385669757.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4385157130","https://openalex.org/W4391450096","https://openalex.org/W3213062408","https://openalex.org/W4365455149","https://openalex.org/W2188898607","https://openalex.org/W4400732757","https://openalex.org/W4386273902","https://openalex.org/W4401920642","https://openalex.org/W2290987402","https://openalex.org/W2088707004"],"abstract_inverted_index":{"Introduction":[0],"Paliperidone":[1],"palmitate":[2,11],"6-month":[3],"(PP6M),":[4],"administered":[5],"twice-yearly,":[6],"demonstrated":[7,242],"non-inferiority":[8],"to":[9,74,164,174,212],"paliperidone":[10],"3-month":[12],"(PP3M)":[13],"in":[14,17,21,52,236,243],"preventing":[15],"relapse":[16,63,95],"patients":[18,53,160,190,209,217],"with":[19,54,228],"schizophrenia":[20],"a":[22,33],"phase-3":[23],"randomized,":[24],"double-blind":[25],"(DB)":[26],"global":[27],"study.1":[28],"We":[29],"report":[30],"results":[31],"of":[32,39,50,151,273],"2-year":[34,250],"single-arm,":[35],"open-label":[36],"extension":[37],"(OLE)":[38],"this":[40,249],"study":[41,61,245,252],"(NCT04072575).":[42],"Objectives":[43],"To":[44],"assess":[45],"long-term":[46],"efficacy":[47],"and":[48,66,89,98,106,111,130,202,214,239,253,351],"safety":[49,256],"PP6M":[51,80,152,229],"schizophrenia.":[55],"Methods":[56],"Patients":[57,77],"who":[58],"completed":[59,139],"DB":[60,244],"without":[62],"were":[64,147,199,223,246,258],"enrolled":[65],"followed":[67],"up":[68,73],"every":[69],"3":[70],"months":[71],"for":[72],"2":[75],"years.":[76],"received":[78],"4":[79],"injections":[81],"(700/1000":[82],"mg":[83],"eq.)":[84],"at":[85],"baseline,":[86],"6-month,":[87],"12-month,":[88],"18-month":[90],"visits.":[91],"Efficacy":[92],"endpoints":[93],"included":[94],"rate,":[96],"Positive":[97],"Negative":[99],"Syndrome":[100],"Scale":[101],"(PANSS)":[102],"total":[103,177],"score,":[104,110,178],"Personal":[105],"Social":[107],"Performance":[108],"(PSP)":[109],"Clinical":[112,234],"Global":[113],"Impression-Severity":[114],"(CGI-S)":[115],"scale":[116],"change":[117,171],"from":[118,172],"baseline.":[119],"Safety":[120],"was":[121,154,230],"assessed":[122],"by":[123],"treatment-emergent":[124],"adverse":[125],"events":[126],"(TEAEs),":[127],"physical":[128],"examinations":[129],"laboratory":[131],"tests.":[132],"Results":[133],"Of":[134],"178":[135],"patients,":[136],"154":[137],"(86.5%)":[138],"the":[140],"study;":[141],"mean":[142],"age:":[143],"40.4":[144],"years;":[145],"70.8%":[146],"men.":[148],"Mean":[149,169],"duration":[150],"exposure":[153],"682.1":[155],"days.":[156],"Overall,":[157,188],"7/178":[158],"(3.9%)":[159],"relapsed":[161],"between":[162],"20":[163],"703":[165],"days":[166],"after":[167],"enrolment.":[168],"(SD)":[170],"baseline":[173],"endpoint:":[175],"PANSS":[176],"0.7":[179],"(8.22);":[180],"CGI-S,":[181,238],"0.0":[182],"(0.51);":[183],"PSP":[184,240],"Scale,":[185],"0.5":[186],"(7.47).":[187],"111/178":[189],"(62.4%)":[191],"reported":[192],"\u22651":[193],"TEAE;":[194],"most":[195],"common":[196],"(>10%)":[197],"TEAEs":[198],"headache":[200],"(13.5%)":[201],"blood":[203],"prolactin":[204],"increased":[205],"(10.7%).":[206],"Total,":[207],"7/24":[208],"withdrew":[210],"due":[211],"TEAEs,":[213],"8/178":[215],"(4.5%)":[216],"experienced":[218],"serious":[219],"TEAEs;":[220],"no":[221,254],"deaths":[222],"reported.":[224],"Conclusions":[225],"Relapse":[226],"rate":[227],"very":[231],"low":[232],"(<4%).":[233],"improvements":[235],"PANSS,":[237],"scales":[241],"maintained":[247],"during":[248],"OLE":[251],"new":[255],"concerns":[257],"identified.":[259],"Reference":[260],"1.":[261],"D.":[262,275],"Najarian":[263,276],"et":[264],"al.":[265],"Int":[266],"J":[267],"Neuropsychopharmacol.":[268],"2022":[269],"Mar":[270],"17;25(3):238-251.":[271],"Disclosure":[272],"Interest":[274],"Shareolder":[277,291,360,372],"of:":[278,283,292,297,306,313,344,361,366,373,378],"Johnson":[279,293,362,374],"&":[280,286,294,300,363,375,381],"Johnson,":[281,295,364,376],"Employee":[282,296,365,377],"Janssen":[284,298,340,352,379],"Research":[285,299,325,380],"Development,":[287,301],"LLC,":[288,302],"I.":[289],"Turkoz":[290],"S.":[303,358],"Galderisi":[304],"Consultant":[305],"Janssen,":[307,317],"Gedeon":[308,315],"Richter-Recordati,":[309,316],"Angelini,":[310,314],"Speakers":[311,342],"bureau":[312,343],"Lundbeck,":[318,331],"Sunovion,":[319,338],"Recordati,":[320],"H.":[321],"Lamaison":[322],"Grant":[323],"/":[324],"support":[326],"from:":[327],"Novartis,":[328],"Eli":[329],"Lilly,":[330],"Servier,":[332,345],"AstraZeneca,":[333],"Wyeth,":[334],"Pfizer,":[335],"Otsuka,":[336],"Takeda,":[337],"Roche,":[339],"Pharmaceutical,":[341,353],"Abbot,":[346],"Raymonds,":[347],"Raffo,":[348],"Temis":[349],"Lostalo":[350],"P.":[354],"Zalitacz:":[355],"None":[356],"Declared,":[357],"Aravind":[359],"Advarra,":[367],"Inc.":[368],"USA,":[369],"U.":[370],"Richarz":[371],"Development-Cilag,":[382],"Switzerland.":[383]},"counts_by_year":[{"year":2023,"cited_by_count":2}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2023-08-09T00:00:00"}